1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

JPM Parting Shots: Milestones Ahead For Prothena, Sage, Aimmune, UniQure

 
• By Mandy Jackson

It takes weeks to recover from the biopharma industry's yearly pilgrimage to San Francisco, so as Scrip continues to sort through notes taken and business cards collected during the 34th Annual J.P. Morgan Healthcare Conference from Jan. 11 to 14, we've put together some pipeline updates from interviews that didn't make it into our initial reporting from the meeting.

It takes weeks to recover from the biopharma industry's yearly pilgrimage to San Francisco, so as Scrip continues to sort through notes taken and business cards collected during the 34th Annual J.P. Morgan Healthcare Conference from Jan. 11 to 14, we've put together some pipeline updates from interviews that didn't make it into our initial reporting from the meeting.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

Incyte’s Povorcitinib Looks Approvable In HS, But How Competitive?

 
• By Joseph Haas

Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.

J&J Dreams Of ICONIC Status For Icotrokinra

 
• By Kevin Grogan

Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.

More from Therapy Areas

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.